RCM
GRNAW

Radcliffe Capital Management’s GreenLight Biosciences Holdings, PBC Warrant GRNAW Stock Holding History

Radcliffe Capital Management’s Portfolio GRNAW Stock Details GRNAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,650
Closed -$225K – 1268
2021
Q4 		$225K Sell
22,650
-2,350
-9% -$2.68K 0.01% 1023
2021
Q3 		$247K Hold
25,000
– – 0.01% 863
2021
Q2 		$245K Buy
+25,000
New +$22.1K 0.01% 889

Other funds holding GRNAW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Radcliffe Capital Management's GRNAW Position: Q1 2022 in Review

Radcliffe Capital Management sold out of GreenLight Biosciences Holdings, PBC Warrant (GRNAW) in Q1 2022, closing a stake of 22,650 shares — an estimated $225K sold.

Radcliffe Capital Management first reported a position in GRNAW in Q2 2021 and held it in 3 quarters. The position peaked at $247K in Q3 2021. 27 funds tracked by Wall St. Rank hold GRNAW as of Q1 2022.

  • Radcliffe Capital Management reported no remaining GreenLight Biosciences Holdings, PBC Warrant position as of Q1 2022 after selling out during the quarter.
  • Radcliffe Capital Management sold 22,650 GreenLight Biosciences Holdings, PBC Warrant shares in Q1 2022, an estimated $225K.
  • Radcliffe Capital Management first reported a position in GreenLight Biosciences Holdings, PBC Warrant in Q2 2021 and held it in 3 quarters.
  • Radcliffe Capital Management's GreenLight Biosciences Holdings, PBC Warrant position peaked at $247K in Q3 2021.
  • 27 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Warrant as of Q1 2022.

Based on Radcliffe Capital Management's 13F filing for Q1 2022, filed 16 May 2022.